Was Patrick Burnett’s ARQT share sale made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is not marked as an affirmative plan for this Form 4, and the footnote describes the sale as covering tax withholding obligations on RSU vesting, with no reference to a 10b5-1 plan.

Arcutis (ARQT) CMO sells shares to cover RSU taxes

Q: At what price were Patrick Burnett’s ARQT shares sold?

Patrick Burnett’s 1,697 ARQT shares were sold at $27.00 per share. The filing identifies this as the transaction price for the reported sale of common stock.

Q: Why did Patrick Burnett sell 1,697 ARQT shares according to the Form 4?

A footnote explains that the sale of 1,697 shares by Patrick Burnett was to cover tax withholding obligations arising from the vesting of his Restricted Stock Units, rather than a discretionary sale of investment holdings.

Q: How many ARQT shares does Patrick Burnett hold after this transaction?

After the reported sale, Patrick Burnett directly holds 117,592 shares of Arcutis Biotherapeutics common stock. This post-transaction holding is stated in the Form 4.

Q: What type of equity award is linked to this ARQT insider sale?

The sale is linked to the vesting of Restricted Stock Units. The footnote states that the shares were sold to cover tax withholding obligations in connection with RSU vesting.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) reported that EVP and Chief Medical Officer Patrick Burnett sold 1,697 shares of common stock on 2026-08-19 at $27.00 per share. A footnote states the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units, leaving him with 117,592 shares directly held.

Insider Trade Summary

Net Seller: 1,697 shares

Net Sell 1 txn

Insider Burnett Patrick

Role See Remarks

Sold 1,697 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	1,697	$27.00	$46K

Holdings After Transaction: Common Stock — 117,592 shares (Direct)

Footnotes (1)

F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Key Figures

Shares sold: 1,697 shares of Common Stock Sale price per share: $27.00 per share Shares owned after transaction: 117,592 shares

3 metrics

Shares sold 1,697 shares of Common Stock Non-derivative sale on 2026-08-19

Sale price per share $27.00 per share Price for the 1,697 shares sold

Shares owned after transaction 117,592 shares Direct holdings of Patrick Burnett following the sale

Key Terms

Restricted Stock Units, tax withholding obligations, Form 4

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

Form 4 regulatory

"The sale reported on this Form 4 represents shares sold"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did ARQT report for Patrick Burnett on this Form 4?

The filing reports that Patrick Burnett, EVP and Chief Medical Officer of Arcutis Biotherapeutics (ARQT), sold 1,697 shares of common stock on 2026-08-19. The transaction is coded as a sale of non-derivative common stock.

At what price were Patrick Burnett’s ARQT shares sold?

Patrick Burnett’s 1,697 ARQT shares were sold at $27.00 per share. The filing identifies this as the transaction price for the reported sale of common stock.

Why did Patrick Burnett sell 1,697 ARQT shares according to the Form 4?

A footnote explains that the sale of 1,697 shares by Patrick Burnett was to cover tax withholding obligations arising from the vesting of his Restricted Stock Units, rather than a discretionary sale of investment holdings.

How many ARQT shares does Patrick Burnett hold after this transaction?

After the reported sale, Patrick Burnett directly holds 117,592 shares of Arcutis Biotherapeutics common stock. This post-transaction holding is stated in the Form 4.

What type of equity award is linked to this ARQT insider sale?

The sale is linked to the vesting of Restricted Stock Units. The footnote states that the shares were sold to cover tax withholding obligations in connection with RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 04:08 PM Accepted by SEC EDGAR 08/21/2026 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/19/2026		S⁽¹⁾		1,697	D	$27	117,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Remarks:

Reporting Person's title: EVP, Chief Medical Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR